The Motley Fool
19 Jul 2026, 11:15 UTC · 1d ago
Looking for Cheap Income Stocks? Why Pfizer Belongs on Your Shortlist Right Now
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
19 Jul 2026, 11:15 UTC · 1d ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Pfizer's dividend payout ratio is currently above 130%, raising concerns regarding the safety of its dividend. — A payout ratio significantly over 100% suggests the dividend may be unsustainable based on current earnings, increasing the risk of a dividend cut.
-0.60Pfizer faces several major patent expirations, which typically lead to generic competition and declining revenues. — Patent cliffs represent a material loss of exclusive revenue streams for pharmaceutical companies.
-0.40Pfizer abandoned its GLP-1 weight-loss drug development in early 2025, leaving it behind key competitors. — Failure in the high-growth GLP-1 market limits the company's potential for significant near-term growth.
-0.30Continue reading
6 related stories
Top 1 mover · tap to explore
Pfizer has acquired a company with a new weight-loss drug candidate and maintains other drugs in its pipeline to offset patent losses. — Acquisition and pipeline progress provide a path to recover growth and replace expiring revenue.
+0.30Pfizer's share price has fallen over 50% from its 2021 highs, pushing its dividend yield to a historically high 6.9%. — The deep discount and high yield may attract value and income investors, providing a floor for the stock price.
+0.20Which stocks this story touches
The company faces headwinds from patent expirations and a failed GLP-1 drug, though it is presented as a potentially attractive value play for aggressive dividend investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Zacks Investment Research
1h ago
